TRENTON, New Jersey (AP) -- Biotech drugmaker Amgen Inc. says its third-quarter profit jumped 24 percent and beat analysts' expectations as sales of more than a half-dozen of its drugs increased by double digits.
Amgen, which sells arthritis treatment Enbrel and Prolia for osteoporosis, says net income was $1.37 billion, or $1.79 per share, up from $1.11 billion, or $1.41 per share, a year earlier.
The Thousand Oaks, California-based company says earnings were $1.94 per share excluding one-time items. Analysts were expecting $1.76 per share.
Revenue was up 10 percent at $4.75 billion. Analysts expected $4.6 billion.
The company also raised the lower end of its 2013 profit forecast by a nickel and now expects $7.35 to $7.45 per share.